Recently, Shanghai No.1 Pharmaceutical Co., Ltd. released its 2025 earnings forecast, expecting net profit attributable to shareholders of the listed company to be approximately RMB 18 million, a year-on-year decline of over 61.98%. The company attributed the sharp profit drop to multiple factors: intensified competition in the pharmaceutical retail sector, coupled with ongoing tightening of national healthcare insurance cost-control policies, has pressured sales of certain high-margin products. Additionally, the company’s proactive efforts to optimize its product mix and invest in store transformation and digital upgrades have weighed on short-term profitability. Furthermore, the high base from non-recurring gains—such as asset disposals—in the same period last year has amplified the year-over-year decline. Despite the earnings pressure, No.1 Pharmaceutical emphasized that its core business remains stable, with its supply chain and regional retail network intact. Moving forward, the company plans to focus on refined management, enhanced customer service, and expansion into new health-consumption scenarios to drive sustainable long-term growth.
近日，上海第一医药股份有限公司发布2025年业绩预告，预计全年归属于上市公司股东的净利润约为1800万元，同比下降超过61.98%。公司表示，利润大幅下滑主要受多重因素影响：一方面，医药零售市场竞争加剧，叠加医保控费政策持续收紧，导致部分高毛利产品销售承压；另一方面，公司主动优化商品结构、推进门店转型及数字化升级，相关投入短期内对利润形成一定拖累。此外，上年同期因资产处置等非经常性损益基数较高，也使得今年同比降幅更为显著。尽管盈利承压，第一医药强调其主营业务仍保持稳健运营，供应链体系和区域零售网络优势未受影响。未来公司将聚焦精细化管理、提升服务能力和拓展健康消费新场景，以期实现长期可持续增长。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/16481.html